



ZTW

Docket No. 1919/60390-AZ-PCT-US/JPW/GJG/ML

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Arlindo Castelhana, et al.
Serial No. : 10/816,329 Group Art Unit: 1624
Filed : March 31, 2004 Examiner: S. Moore
Title : PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR
USE

1185 Avenue of the Americas
New York, New York 10036
April 10, 2008

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following references, which are listed on Form PTO-1449 **(Exhibit A)**.

Reference items 1 and 2 are U.S. patent application publications. Pursuant to 37 C.F.R. 1.98(a)(2), copies of reference items 1 and 2 are not being submitted.

Reference items 3 and 4 are listed to include the publication year as requested by the Examiner during an April 10, 2008 telephonic conference with the undersigned, copies of which are not being submitted because they were submitted with Applicants' March 19, 2008 Supplemental Information Disclosure Statement.

Applicants: Arlindo Castelhana et al.
Serial No.: 10/816,329
Filed: March 31, 2004
Page 2

Copy of the document listed herein as item 5 is attached hereto as **Exhibit 1**.

1. U.S. Patent Application Publication No. 2003-0029067 A1, published December 11, 2003 (Castelhana, A. et al.);
2. U.S. Patent Application Publication No. 2008-0070936, published March 20, 2008 (Castelhana, A. et al.);
3. Kiichiro, K. et al. (1992) "Synthesis of pyrazinecarboxylic acid derivs. - (II) derivs. of 3-aminopyrazinecarboxylic acid" Chem. Abstracts 56:8713;
4. Mitchell, C.H. et al., (1999) "Adenosine A3 Receptor Activation Reduces Cell Volume and Activates Cl⁻ Current in Human Ciliary Epithelial Cells", *FASEB J*, A134 (Abstract only); and
5. Baraldi et al. (2002) "Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes", *Curr. Pharm. Design* 8: 2299-2332 (**Exhibit 1**).


Applicants request that the Examiner review the references and make them of record in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants: Arlindo Castelhana et al.
Serial No.: 10/816,329
Filed: March 31, 2004
Page 3


No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any other fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Gary J. Gershik
Registration No. 39,992
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this
correspondence is being deposited this
date with the U.S. Postal Service with
sufficient postage as first class mail
in an envelope addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



John P. White Date 4/10/08
Reg. No. 28,678
Gary J. Gershik
Reg. No. 39,992

Exhibit A

Applicants: Arlindo Castelhana, et al.

Serial No.: 10/816,329

Filed: March 31, 2004